Sarclisa was added to the National Comprehensive Cancer Network (NCCN) guidelines for non-transplant multiple myeloma candidates as a category 1 (preferred) option alongside VRd and Darzalex plus ...

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Multiple myeloma is a kind of blood cancer that starts in plasma cells. Inside most of your bones is a soft, spongy tissue called bone marrow. Here, your body makes hundreds of thousands of red ...

Daratumumab plus VRd significantly improves survival in newly diagnosed multiple myeloma, supporting its role as a new ...

New research shows that maintaining a healthy weight following a monoclonal gammopathy of undetermined significance diagnosis ...

T-cell therapy for eligible myeloma patients. The immunotherapy, which harnesses the body’s own immune system to fight blood cancer, will initially be available at HCA at University College Hospital ...

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development.

The updated NCCN Guidelines now include HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant uveal melanoma. Previously, the guidelines limited its use to patients with ...